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Xiaofan Wu, MD, PHD,* Gary S. Mintz, MD,* Kai Xu, MD, PHD,*
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Objectives The aim of this study was to understand the impact of attenuated plaque on distal em-
bolization during stent implantation in patients with acute myocardial infarction (AMI).
Background Attenuated plaques identiﬁed by grayscale intravascular ultrasound (IVUS) might predict tran-
ient deterioration in coronary ﬂow and/or no-reﬂow during percutaneous coronary intervention (PCI).
ethods We analyzed clinical, angiographic, and IVUS data from 364 patients (n  364 infarct-re-
lated arteries) enrolled in the randomized HORIZONS-AMI (Harmonizing Outcomes With Revascular-
ization and Stents in Acute Myocardial Infarction) trial. No-reﬂow was ﬁnal Thrombolysis In Myocar-
dial Infarction (TIMI) ﬂow grade 2 in the absence of mechanical obstruction. Attenuated plaque
as hypoechoic or mixed atheroma with ultrasound attenuation without calciﬁcation. A mean atten-
ation score was created by measuring the angle of attenuation each 1 mm, scoring the angle as
to 4 (corresponding to 90°, 90° to 180°, 180° to 270°, or 270° to 360°, respectively), summing the
cores, and normalizing for analysis length.
esults Overall, 284 (78.0%) patients had attenuated plaques; no-reﬂow occurred in 37 (10.2%). Patients with
o-reﬂow had a higher mean attenuation score (median [interquartile range] 2.2 [0.0 to 2.8] vs. 1.3 [0.7 to 1.8],
 0.001), lower baseline left ventricular ejection fraction (52.8% [43.2% to 61.5%] vs. 61.4% [52.2% to 68.1%],
 0.002), and more baseline angiographic thrombus (89.2% vs. 74.1%, p  0.043) with no differences in
ost-PCI stent expansion versus patients without no-reﬂow. Multivariate analysis indicated that mean attenua-
ion score was the strongest predictor of no-reﬂow. The mean attenuation score that best predicted no-reﬂow
as 2 points (90° to 180°, sensitivity of 81.5%, and speciﬁcity of 80.5%).
onclusions Attenuated plaque was present in three-quarters of patients with AMI. The amount of attenu-
ted plaque strongly correlated with no-reﬂow; the larger the attenuated plaque, the greater the likelihood of
o-reﬂow. (Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the
esults of Using Anticoagulation With Either Unfractionated Heparin  Routine GP IIb/IIIa Inhibition or Bivaliru-
in  Bail-out GP IIb/IIIa Inhibition; and Primary Angioplasty with stent implantation with Either a Slow Rate-
elease Paclitaxel-eluting Stent [TAXUS™] or Uncoated Bare Metal Stent [EXPRESS2™]; NCT00433966) (J Am
oll Cardiol Intv 2011;4:495–502) © 2011 by the American College of Cardiology Foundation
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496Percutaneous coronary intervention (PCI) with stent
implantation is often performed to treat patients with
acute myocardial infarction (AMI). However, PCI fails to
achieve Thrombolysis In Myocardial Infarction (TIMI)
ow grade 3 in 12% to 30% of cases, mainly because of
he no-reflow phenomenon that is associated with poor
unctional and clinical outcomes (1–5). Retrospective
intravascular ultrasound (IVUS) studies have shown that
attenuated plaque (hypoechoic or mixed atheroma with
ultrasound attenuation but without calcification) is com-
mon in acute coronary syndromes and is associated with a high
rate of no-reflow or transient deterioration in coronary flow
during PCI (6,7). The aim of the present study is to use the
data from the HORIZONS-
AMI (Harmonizing Outcomes
With Revascularization and
Stents in Acute Myocardial In-
farction) trial to evaluate the im-
pact of attenuated plaque on no-
reflow in patients with AMI
undergoing primary stent implan-
tation.
Methods
Study population. The HORI-
ZONS-AMI trial was a dual-arm,
factorial, randomized trial in pa-
tients with ST-segment elevation
myocardial infarction (STEMI).
There were 2 randomization steps:
1) unfractionated heparin plus rou-
tine glycoprotein IIb/IIIa inhibi-
tion versus bivalirudin alone (1:1
randomization); and 2) paclitaxel-
eluting TAXUS stents versus bare
metal EXPRESS stents (Boston
Scientific, Natick, Massachusetts)
(3:1 randomization). A formal
IVUS substudy enrolled 464 pa-
tients with baseline and 13-month
ollow-up imaging at 36 centers. The primary pre-
pecified endpoint of the IVUS substudy has been re-
orted previously (8).
Foundation, with grant support from Boston Scientific and The Medicines Company.
Drs. Mintz, Dressler, and Parise report being employed by the Cardiovascular
Research Foundation. Dr. Stone is a member of the scientific advisory boards for and
has received honoraria from Abbott Vascular and Boston Scientific and has served as
consultant to Volcano Corporation. Dr. Mintz reports receiving honoraria and
research support from Volcano Corporation; and honoraria and research fellowship
support from Boston Scientific. Dr. Guagliumi reports receiving consulting fees from
Volcano Corporation and Boston Scientific; and research grants from Medtronic
Vascular, Boston Scientific, Lightlab, and Abbott Vascular. Drs. Mintz, Lansky,
Abbreviations
and Acronyms
AMI  acute myocardial
nfarction
K-MB  creatine kinase-
yocardial band
TFC  corrected
hrombolysis In Myocardial
nfarction frame count
B  integrated backscatter
VUS  intravascular
ltrasound
AD  left anterior
escending coronary artery
VEF  left ventricular
jection fraction
LA  minimum lumen area
LD  minimum lumen
iameter
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarction
H  virtual histologyGuagliumi, Stone, and Maehara report receiving research grants from Boston MThis study was approved by the institutional review
oards of the institutions in which the procedures were
erformed. Written informed consent was obtained from all
atients before cardiac catheterization.
Clinical data were collected and included risk factors, left
entricular ejection fraction (LVEF) (evaluated by left
entriculography), and creatine kinase-myocardial band (CK-
B) levels.
Quantitative and qualitative coronary angiography. Coro-
ary angiograms at baseline and immediately after PCI were
erformed in at least 2 orthogonal views after intracoronary
itroglycerin. Angiograms were analyzed at the Angiographic
ore Laboratory of the Cardiovascular Research Foundation
New York, New York), which was blinded to the clinical and
VUS findings with the CMS-GFT algorithm (MEDIS,
eiden, the Netherlands). Minimum lumen diameter (MLD)
nd mean reference vessel diameter (RVD), obtained by
veraging 5-mm segments proximal and distal to the target-
esion, were used to calculate diameter stenosis: ([1  MLD/
VD]  100%). Angiographic coronary blood flow was
ssessed at baseline and after PCI on the basis of TIMI flow
rade (9) and corrected Thrombolysis In Myocardial infarction
rame count (CTFC) (10). No-reflow was defined as final
IMI flow grade 0 and 1 or 2 in the absence of mechanical
bstruction. Qualitative analysis was done with standard meth-
ds (11). Presence or absence of intracoronary thrombus (hazy,
lobular filling defect, or total occlusion) and calcification were
valuated.
IVUS imaging and analysis. The IVUS was performed after
successful, uncomplicated stent implantation. Allowable
IVUS systems included iLab, Galaxy, or Clearview (all with
Atlantis SR Pro, 40-MHz catheters [Boston Scientific]) or
In Vision Gold with 20-MHz EagleEye catheters (Volcano
Therapeutics, Rancho Cordova, California). The IVUS
imaging was performed with motorized pullback (0.5 mm/s)
to include the stent and 5-mm segments proximal and
distal to the stent. The IVUS studies were archived and sent
to an independent, treatment-allocation-blinded IVUS core
Laboratory (Cardiovascular Research Foundation, New
York, New York) for quantitative and qualitative analyses
with validated software (EchoPlaque, INDEC Systems,
Inc., Mountain View, California).
Quantitative analysis included measurement of external
elastic membrane, stent, lumen, and plaquemedia (PM
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497 external elastic membrane  lumen) cross-sectional areas
every 1 mm. Qualitative analysis included: 1) attenuation
behind the plaque in the absence of calcification;
2) intra-stent plaque and/or thrombus protrusion (IVUS
cannot reliably differentiate between plaque vs. thrombus
that protrudes through stent struts); 3) intra-plaque echo-
lucent zone (absence of ultrasound signal within the
plaque); and 4) edge dissection (tangential tear in the plaque
at the stent edge).
As previously reported, a mean attenuation score was
created by measuring the angle of attenuation each 1 mm,
scoring the angle as 1, 2, 3, or 4 points when the attenuation
angle was 90°, 90° to 180°, 180° to 270°, or 270° to 360°,
respectively; summing the scores to create an overall atten-
uation score; and finally, normalizing for analysis length
(Fig. 1) (12). Plaque without attenuation was scored as 0
points. The presence of attenuation and the mean attenua-
tion scores were analyzed by 2 independent, experienced
observers (X.W. and A.M.), and consensus interpretation
was included in the subsequent analysis.
Intraobserver and interobserver variability and reliability analysis.
All lesions were analyzed 3 months apart to assess intraob-
server and interobserver variability in the identification of
attenuated plaque; both intraobserver (kappa  0.96) and
interobserver (kappa  0.94) variability yielded good con-
ordance. To assess the reproducibility of the mean atten-
ation score, 100 consecutive lesions were analyzed by 2
bservers (X.W. and A.M.); the difference in the mean
ttenuation score after stenting was 0.08  0.23 points, and
he intraclass correlation coefficient for repeated measure-
ent was 0.98.
Although only post-stent IVUS was pre-specified in the
ORIZONS protocol, pre-PCI IVUS was performed in 40
Figure 1. Attenuation Score
Attenuation score was 1, 2, 3, or 4 points when the attenuation angle was 9
tion angle was 120°; therefore, attenuation score was 2 points.atients at the discretion of the operator. We used images from
hese 40 patients to compare attenuation detection and mean
ttenuation score calculation between pre- and post-PCI
VUS studies. In these 40 lesions with both pre- and post-
tenting IVUS, there were 29 attenuated plaques; there was
omplete agreement between the pre-stent and post-stent
ssessment of the presence of IVUS attenuation. The differ-
nce in the calculated mean attenuation score was 0.07 0.12
oints. Intraclass correlation coefficient comparing pre-
ersus post-stenting attenuation was 0.99. An example is
hown in Figure 2.
Statistical analysis. Statistical analysis was performed with
SAS software (version 9.1, SAS Institute, Inc., Cary, North
Carolina). Categorical variables were compared with chi-
square statistics or Fisher exact test. Continuous variables
were compared with Wilcoxon rank-sum test and displayed
as median (interquartile range). The cutoff of mean atten-
uation score was calculated by receiver-operator character-
istic curve to predict no-reflow. The optimal cut-point was
selected when the highest sum of sensitivity and specificity
was available. We conducted a stepwise multivariate logistic
regression analysis to identify independent predictors of
no-reflow. The model included clinical, angiographic, and
procedural characteristics and quantitative and qualitative
IVUS findings with p  0.20 in the univariate analyses. A
p value 0.05 was considered to indicate statistical
significance.
Results
Between March 25, 2005, and May 7, 2007, 402 patients
(429 lesions) had analyzable post-PCI and follow-up IVUS
studies. We excluded 11 lesions in saphenous venous
° to 180°, 180° to 270°, or 270° to 360°, respectively. In this picture, attenua-0°, 90
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498grafts, 38 lesions in noninfarct-related arteries, and 16
lesions with unreliable pullback or zoom or gain not
appropriate to evaluate attenuated plaque. Eventually,
364 de novo infarct-related coronary artery lesions in 364
patients were included.
Clinical characteristics. Overall, 78.8% (287) were men; the
median patient age was 60.3 (51.3 to 68.9) years; 39.0%
(n  142) had infarct-related left anterior descending
coronary artery (LAD) lesions; pre-intervention angio-
graphic thrombus was present in 75.0% (n  273); 73.1%
(n  266) had a pre-PCI TIMI flow grade 2; and
re-PCI LVEF was 61.0% (51.4% to 67.6%). As shown
n Table 1, there were no statistically significant differ-
nces between patients with and without no-reflow ex-
ept: 1) no-reflow was associated with lower CK-MB;
Figure 2. Mean Attenuation Score Before and After PCI
A and B were longitudinal sections through same lesion before and after perc
measuring the attenuation angle each 1 mm (cross-section of lesion before PC
and normalizing for analysis length. A0 and B0 were bifurcation markers. Pre-
respectively. The corresponding attenuation scores were 1, 1, 2, 2, and 1 point
B1 to B5 were 45°, 55°, 105°, 110°, and 55°, respectively; the corresponding at
7/4.8  1.5.) patients with no-reflow had higher CK-MB before and after PCI; and 3) there were fewer current smokers in
he no-reflow group.
Angiographic and procedural ﬁndings. As shown in Table 2,
atients with no-reflow more often had PCI of an LAD than
non-LAD lesion (59.5% vs. 36.7%, p  0.026). Baseline
ngiographic thrombus was more frequent in patients with
ersus without no-reflow (89.2% vs. 74.1%, p  0.043).
re-PCI TIMI flow grade 0 to 2 was more common in patients
ith versus without no-reflow (86.5% vs. 71.2%, p  0.047);
imilarly, pre-PCI CTFC was higher in no-reflow patients
41.0 [29.0 to 52.5] vs. 30.0 [20.0 to 40.0], p  0.032). Final
ngiographic diameter stenosis was larger in patients with
o-reflow (23.1% [16.6% to 27.3%] vs. 17.7 [12.6% to 23.8%],
 0.004), whereas acute gain was similar between the 2
roups. The use of pre-dilation and post-dilation, balloon size,
ous coronary intervention (PCI). Mean attenuation score was analyzed by
to A5; cross-section of lesion after PCI: B0 to B5), then summing the scores,
) attenuation angles of slices A1 to A5 were 40°, 55°, 95°, 105°, and 60°,
mean attenuation score was 7/4.8  1.5. Post-PCI (B) attenuation angles of
ion score were 1, 1, 2, 2, and 1 points, yielding a mean attenuation score ofutane
I: A0
PCI (A
s; the
tenuatnd balloon/artery ratio were similar between the 2 groups.
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499Grayscale IVUS image analysis. As summarized in Table 3,
there were no statistically significant quantitative differ-
ences between patients with and those without no-reflow.
The frequency of plaque/thrombosis protrusion and
echolucent plaque was also similar between the 2 groups.
Attenuated plaque and no-reﬂow. Overall, 78.0% (n 284)
of the patients had attenuated plaques, and 10.2% (n  37)
had no-reflow. There were 284 (78.0%) attenuated plaques
in the stented segment and 122 (33.5%) in the proximal or
distal unstented reference vessels, 115 of which (94.3%)
were located both within the stented segment and in the
reference segment, whereas 7 (5.7%) were located only in
the reference segments (p  0.001).
The mean attenuation score was significantly higher (2.2
[0 to 2.8] vs. 1.3 [0.7 to 1.8], p  0.001), whereas the mere
presence of attenuated plaque (73.0% vs. 78.4%, p  0.434)
and attenuation length (6.9 [0.0 to 16.9] mm vs. 8.0 [2.6 to
14.0] mm, p  0.874) were similar in patients with versus
without no-reflow. The mean attenuation score that best
predicted no-reflow was2 points (attenuation angle90°)
ith a sensitivity of 81.5%, a specificity of 80.5%, and an
rea under the receiver-operator characteristic curve of
.883. Final CTFC was significantly higher in patients with
mean attenuation score 2 points (24.0 [16.0 to 38.0])
ersus patients with a mean attenuation score 2 points
19.0 [15.0 to 26.0], p  0.001) versus patients without
ttenuation (20.0 [16.0 to 28.0], p  0.02).
In 284 patients with attenuated plaques, no-reflow was
ssociated with older patient age (66.1 [59.0 to 73.4]
ears vs. 60.4 [52.1 to 70.0] years, p  0.013), lower
VEF (50.6% [43.0% to 61.6%] vs. 59.9% [50.6% to
7.4%], p  0.008), and LAD lesion location (70.4% vs.
7.0%, p  0.004). In 80 patients without attenuated
Table 1. Baseline Clinical Characteristics
No-Reflow
(n  37)
Reflow
(n  327) p Value
Age, yrs 63.6 (55.7–73.2) 59.1 (50.7–68.7) 0.105
Male 30 (81.1) 257 (78.6) 0.725
Hypertension 18 (48.6) 166 (50.8) 0.807
Hyperlipidemia 9 (24.3) 129 (39.4) 0.072
BMI, kg/m2 27.3 (25.7–28.7) 27.0 (24.5–30.0) 0.538
Diabetes 2 (5.4) 45 (13.8) 0.199
Current smoking 11 (29.7) 167 (51.1) 0.014
Family history of CAD 11 (29.7) 126 (38.5) 0.295
LVEF, % 52.8 (43.2–61.5) 61.4 (52.2–68.1) 0.002
Baseline CK-MB, mg/dl 23.1 (9.5–91.5) 13.1 (4.4–32.5) 0.016
Peak CK-MB after PCI, mg/dl 323.0 (182.9–440.2) 215.0 (93.0–375.9) 0.025
∆CK-MB, mg/dl 256.0 (109.5–354.9) 170.0 (55.2–348.9) 0.259
Bivalirudin 17 (45.9) 169 (51.7) 0.603
Values are median (interquartile range) or n (%).
BMI body mass index; CAD coronary artery disease; CK-MB creatine kinase-myocardial
band; LVEF left ventricular ejection fraction; PCI percutaneous coronary intervention.laques, no-reflow was only associated with angiographichrombosis before PCI (20% vs. 0%, p 0.014) as well as the
requency of pre-dilation (90.0% vs. 46.5%, p  0.015) and
ost-dilation (70.0% vs. 28.2%, p  0.014).
Independent predictors of no-reflow included mean
ttenuation score 2 (odds ratio: 6.586, 95% confidence
nterval: 2.680 to 16.188, p  0.001) and angiographic
hrombosis before PCI (odds ratio:  9.143, 95% confi-
ence interval: 1.182 to 70.732, p  0.034). However,
ean attenuation score 2 points had nearly 10 times the
ikelihood of no-reflow as mean attenuation score 2 points.
aseline TIMI flow grade and CTFC, target lesion length,
nfarct-related LAD lesion location, and echolucent plaque
dentified by IVUS did not correlate with no-reflow in this
odel.
iscussion
The major findings in the present study were that attenu-
ated plaque was present in three-quarters of patients with
Table 2. Angiographic and Procedure Characteristics
No-Reflow
(n  37)
Reflow
(n  327) p Value
Infarct-related artery 0.026
Left anterior descending 22 (59.5) 120 (36.7)
Left circumﬂex 5 (13.5) 53 (16.2)
Right coronary artery 10 (27.0) 154 (47.1)
Before PCI
Lesion length, mm 12.8 (10.0–18.6) 16.0 (11.2–22.3) 0.036
RVD, mm 3.0 (2.7–3.4) 3.0 (2.7–3.3) 0.282
MLD, mm 0.0 (0.0–0.5) 0.0 (0.0–0.5) 0.697
DS, % 100 (85.0–100) 100 (81.6–100) 0.549
Thrombus 33 (89.2) 240 (74.1) 0.043
TIMI ﬂow grade 0/1/2 32 (86.5) 232 (71.2) 0.047
CTFC 41.0 (29.0–52.5) 30.0 (20.0–40.0) 0.027
After PCI
CTFC 45.5 (38.0–55.0) 19.0 (15.0–26.0) 0.001
RVD, mm 3.1 (2.7–3.4) 3.1 (2.7–3.3) 0.445
MLD, mm 2.3 (2.1–2.8) 2.5 (2.1–2.8) 0.304
DS, % 23.1 (16.6–27.3) 17.7 (12.6–23.8) 0.004
Acute gain, mm 2.1 (1.9–2.5) 2.2 (1.8–2.6) 0.660
Thrombus 2 (5.4) 2 (0.6) 0.053
Procedure
Time to reperfusion, h 4.8 (2.9–7.4) 3.5 (2.6–5.6) 0.048
Before dilation 28 (75.7) 206 (64.2) 0.164
After dilation 20 (54.1) 135 (42.1) 0.163
Aspiration 5 (13.5) 28 (8.8) 0.365
Maximum balloon diameter, mm 3.5 (3.3–4.0) 3.5 (3.0–3.8) 0.075
Maximum balloon: reference 1.16 (1.09–1.22) 1.17 (1.06–1.29) 0.982
Maximum pressure, atm 16.0 (14.0–18.0) 16.0 (14.0–18.0) 0.642
TAXUS use 29 (78.4) 244 (74.6) 0.617
Values are n (%) or median (interquartile range).
CTFC  corrected Thrombolysis In Myocardial Infarction frame count; DS  diameter
stenosis; MLD  minimum lumen diameter; PCI  percutaneous coronary intervention;RVD  reference vessel diameter; TIMI  Thrombolysis In Myocardial Infarction.
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500STEMI. Because attenuated plaque was present in such a
large percentage of STEMI patients, its mere presence did not
predict no-reflow. Instead, the larger the attenuated plaque, the
greater the likelihood of no-reflow; a mean attenuation score
2 points (attenuation angle 90°, indicative of a large,
iffuse attenuated plaque) best-predicted no-reflow (sensi-
ivity of 81.5%, specificity of 80.5%, area under the receiver-
perator characteristic curve of 0.883).
No-reflow is related to capillary occlusion and microem-
oli to coronary resistance vessels (13–16). The capillary
tructure becomes disorganized in the no-reflow zone,
ecause of endothelial swelling, tissue compression, myocyte
dema, and neutrophil infiltration (17,18). This usually
results from a large AMI but can be worsened by reperfu-
sion. No-reflow is also attributed to thrombus and/or plaque
embolization during PCI (19–22). These plaque compo-
nents (including platelet-fibrin complex, macrophages, and
cholesterol crystals) provoke arteriole spasm leading to
further microvascular congestion, thrombosis, and sluggish
coronary flow.
Previous studies have demonstrated that a greater pre-
PCI plaque burden and a decreased plaque volume during
PCI were related to CK-MB elevation after PCI (23–25).
Table 3. Quantitative and Qualitative IVUS Analysis
No-Reflow
(n  37)
Reflow
(n  327) p Value
Reference*
EEM CSA (mm2) 15.6 (12.1–20.0) 15.1 (11.6–18.6) 0.254
Lumen CSA (mm2) 9.7 (8.5–11.9) 9.2 (7.1–11.4) 0.113
PM CSA (mm2) 5.2 (3.0–7.9) 5.5 (4.0–7.4) 0.987
Plaque burden (%) 38.1 (23.9–44.3) 36.4 (29.2–43.8) 0.729
Stent segment
EEM CSA at MLA site (mm2) 14.5 (10.2–19.5) 15.6 (12.1–19.3) 0.653
Lumen CSA at MLA site (mm2) 6.8 (5.3–8.5) 6.7 (5.2–7.8) 0.477
Stent CSA at MLA site (mm2) 7.1 (5.5–9.0) 7.0 (5.5–8.4) 0.589
Focal stent expansion† 0.71 (0.60–0.86) 0.76 (0.66–0.88) 0.073
Diffuse stent expansion† 0.84 (0.79–0.98) 0.90 (0.79–1.02) 0.381
Mean EEM CSA, mm3/mm 17.0 (13.1–20.2) 16.5 (13.8–20.0) 0.993
Mean lumen CSA, mm3/mm 8.3 (7.2–10.5) 8.0 (6.7–9.9) 0.400
Mean stent CSA, mm3/mm 8.8 (7.4–10.3) 8.0 (6.7–10.0) 0.236
Attenuation 27 (73.0) 257 (78.6) 0.434
Overall attenuation score 18.0 (0–43.0) 11.0 (2.0–24.0) 0.134
Attenuation length 6.9 (0–16.9) 8.0 (2.6–14.0) 0.873
Mean attenuation score 2.2 (0–2.8) 1.3 (0.7–1.8) 0.001
Tissue protrusion 24 (64.9) 239 (73.1) 0.290
Echolucent plaque 11 (29.7) 64 (19.6) 0.148
Dissection at stent edge 7 (18.9) 42 (12.8) 0.277
Values are median (interquartile range) or n (%). *Average of proximal and distal (most normal-
looking) reference sites. †Focal stent expansion was calculated as minimum stent area (MSA)
divided by average reference lumen cross-sectional area (CSA); diffuse stent expansion was
calculated as mean stent area divided by average reference lumen CSA.
EEM external elastic membrane; IVUS intravascular ultrasound; MLAminimum lumen
area; PM plaquemedia.However, not only the size of the plaque but its compositionis important in the pathogenesis of no-reflow. Specific
grayscale IVUS plaque characteristics that have predicted
no-reflow or CK-MB elevation after PCI have included a
lipid pool-like image, positive remodeling, intracoronary
mural thrombus, and now attenuated plaque (6,19,21,26).
However, grayscale IVUS has only a limited ability to assess
atherosclerotic plaque composition. Analysis of radiofre-
quency ultrasound backscatter signals known as integrated
backscatter (IB)-IVUS or virtual histology (VH)-IVUS
have been developed to improve on these limitations of
grayscale IVUS. We have recently reported the strong
relationship between attenuated plaque (grayscale IVUS)
and a large amount of necrotic core indicative of a fibro-
atheroma (VH-IVUS) (27). This relationship is supported
by histopathological studies demonstrating that attenuated
plaque is composed of microcalcifications and cholesterol
crystals (28,29). Acute coronary syndromes are most often
caused by thrombosis superimposed on rupture of a thin-cap
fibroatheroma containing a large necrotic core (30,31). Both
IB-IVUS and VH-IVUS studies have suggested that lipid-
rich plaque (IB-IVUS) or necrotic core-rich plaque (VH-
IVUS) are associated with no-reflow (32–35). Thus, atten-
uated plaques represent a large amount of necrotic core
containing fragile tissues such as lipid deposition with foam
cells, cholesterol crystals, and microcalcifications that are
easily embolized by mechanical fragmentation during coro-
nary stenting.
However, the current study also shows that attenuated
plaques are present in three-quarters of infarct-related lesions
of STEMI patients. Thus, it is the size of the attenuated
plaque and not its mere presence that is related to no-reflow.
In a practical way, the current study suggests that culprit
lesions containing a mean attenuation angle 90° have a
higher risk of no-reflow. However, attenuation varies sig-
nificantly over the length of the lesion. In the majority of
infarct-related lesions, the arc of attenuated plaque is180°
(and sometimes circumferential) in the middle of the lesion
and tapers closer to the reference segments. Therefore, the
calculation of a mean attenuation score takes into account
the severity of attenuation at its worst cross-section as well
as its distribution (12,30). However, the frequency of
attenuated plaque is higher in the current study than is
reported by Lee et al. (6) but similar to the study by Okura
et al. (7). The differences are not entirely clear, although
patient selection might be an important explanation.
In the current analysis, attenuated plaque was also asso-
ciated with reduced coronary flow before PCI; the incidence
of pre-PCI TIMI flow grade 0/1 was 77.4% in patients with
attenuated plaque versus 56.8% in patients without attenu-
ated plaque. Previous studies have shown that spontaneous
distal embolism of thrombus or atheromatous gruel from
the epicardial culprit lesion was common in acute coronary
syndromes and might be further triggered by PCI (36,37).
The current study extends these previous observations to
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501suggest that large attenuated plaques might be more likely
to embolize spontaneously before PCI as well as after
balloon dilation and stent implantation.
Study limitations. This was a retrospective analysis. How-
ever, data were collected prospectively by independent
monitors at each site. In most patients, IVUS was only
performed after stenting (according to the established pro-
tocol). However, in the subset of patients with both pre-
and post-stent IVUS, there were no significant differences
in the presence or amount of attenuated plaque comparing
pre- versus post-stenting studies; and reliability analysis
showed excellent repeat measurements. There were 262
cases with a mechanical catheter (40 MHz, Boston Scien-
tific) and 102 cases with a solid state catheter (20 MHz,
Volcano Corporation). Although attenuated plaques were
more common in patients with mechanical catheters versus
solid state catheters (82.8% vs. 65.7%, p  0.001), the
frequency of no-reflow versus reflow was similar in mechan-
ical catheters (72.2% vs. 70.3%) and in solid state catheters
(27.8% vs. 29.7%) (p  0.807). The number of variables
ncluded in our multivariate logistic regression analysis
ight lead to overfitting, due to the low number of events
n 37). However the final model is parsimonious, because
nly 2 variables were selected. Finally, we did not assess the
mount of attenuated plaque, per se, but the attenuation
ngle. The pre- versus post-stent comparison in the current
nalysis indicates that the angle of attenuation does not
hange, even though plaque was embolized as indicated by
he CK-MB changes (in the current study) and changes in
laque mass reported in previous studies (7,38).
Conclusions
Attenuated plaque is present in three-quarters of patients
with AMI. The extent of the attenuation rather than its
mere presence is strongly correlated with no-reflow; the
larger the attenuated plaque, the greater the likelihood of
no-reflow.
Reprint requests and correspondence: Dr. Akiko Maehara,
Cardiovascular Research Foundation, 111 East 59th Street, New
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